Source: Annual Congress 2008 - Therapy of thoracic tumours
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. Endo, Y. Ohno, F. Ito, H. Mori, N. Funaguchi, B. L. Bai La, K. Gotoh, S. Minatoguchi (Gifu, Japan). Granulocyte colony-stimulating factor enhances the anticancer effects of cisplatin against lung cancer by promoting angiogenesis. Eur Respir J 2008; 32: Suppl. 52, 4303

Member's Comments

No comment yet.

Related content which might interest you: The growth of lung cancer cells is progressed by G-CSF and M-CSF due to activation of angiogenesis Source: Eur Respir J 2003; 22: Suppl. 45, 224s Year: 2003 Interleukin-17 enhances the net angiogenic potential and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis Source: Eur Respir J 2004; 24: Suppl. 48, 79s Year: 2004 Effects of chemotherapeutic drugs and TRAIL (tumor necrosis factor-related apoptosis inducing ligand) on the non-small lung cancer cells Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Synergistic effect of cysteinyl-leukotrienes and epidermal growth factor on human lung fibroblast mitogenesis Source: Eur Respir J 2005; 26: Suppl. 49, 340s Year: 2005 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Overexpression of fibroblast growth factor and down-regulation of platelet-derived growth factor correlate with advanced-stage lung fibrosis Source: Annual Congress 2010 - Cell biology and immunology of lung disease Year: 2010 Some of the tumor necrosis factor receptor superfamilies and their concentrations in serum during chemotherapy of lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006 Inhibition of proliferation of lung cancer cells by CD40 signaling through tumor necrosis factor I Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Apoptosis, tumor cell proliferation and angiogenesis as prognostic factor in lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019 Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer Source: Eur Respir J 2011; 37: 183-193 Year: 2011 Targeted therapy in nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 284–298 Year: 2009 The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Association of genetic variations in the CSF2 and CSF3 genes with lung function in smoking-induced COPD Source: Eur Respir J 2008; 32: 25-34 Year: 2008 Adenovirus-mediated interferon-beta gene therapy inhibits tumor growth and inhibits metastatic lung tumors in mice Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002 Validation of a new serum granulocyte–macrophage colony-stimulating factor autoantibody testing kit Source: ERJ Open Res, 6 (1) 00259-2019; 10.1183/23120541.00259-2019 Year: 2020 Dimethylfumarate reduces growth factor- and cytokine-induced IL-6 release from human lung fibroblasts: role of (NF)-κB Source: Annual Congress 2008 - Airway cell biology and immunology Year: 2008